Clinical Trial Update: OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients [Phase 3]

View source ↗

Summary

Phase 3 trial updates on re-treatment and step-up therapy with omalizumab for chronic spontaneous urticaria (CSU) completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: COMPLETED | Results posted: 2018-08-08